An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Glaukos Corporation (NYSE: GKOS) will announce its third quarter 2021 financial results after market close on November 4, 2021. A conference call and webcast will follow at 1:30 p.m. PDT. Investors can access the live webcast via the company's website. The company specializes in innovative treatments for glaucoma, corneal disorders, and retinal diseases, including the pioneering Micro-Invasive Glaucoma Surgery (MIGS) and its iStent® devices.
Positive
Pioneering solutions in glaucoma treatment with MIGS.
Established product lineup including iStent® devices launched since 2012.
Focus on comprehensive therapies across glaucoma, corneal health, and retinal disease.
Negative
None.
Conference Call and Webcast Scheduled for 1:30 p.m. PDT
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2021 financial results after the market close on Thursday, November 4, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on November 4, 2021.
A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
When will Glaukos release its third quarter 2021 results?
Glaukos will release its third quarter 2021 financial results after market close on November 4, 2021.
What time is Glaukos' conference call on November 4, 2021?
The conference call will take place at 1:30 p.m. PDT on November 4, 2021.
How can I access Glaukos' conference call?
You can access the conference call by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) and entering Conference ID 7935742.
What is Glaukos Corporation known for?
Glaukos is known for its innovative therapies for treating glaucoma and corneal disorders, particularly through Micro-Invasive Glaucoma Surgery (MIGS).
